 |
 | | | | | | | |
| | |
New Guidance on Extended-Release Injectable Naltrexone SAMHSA has issued new guidance based on a review of the current evidence on the effectiveness of available medications for the treatment of opioid use disorders. The guide includes a summary of the key differences between extended-release injectable naltrexone, methadone, and buprenorphine. Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorders: A Brief Guideprovides key information on assessing the patient's need for treatment and initiating medication-assisted treatment (MAT). It also advises on how to monitor patient progress, adjust the treatment plan, and decide whether and when to end MAT. Extended-release injectable naltrexone can be used to expand access to treatment of an opioid use disorder in medical office settings, rather than limiting use to specialized opioid treatment programs. These new medications can help fill the unmet need for treatment through the largely untapped resource of primary care clinicians. |
.png)
No hay comentarios:
Publicar un comentario